rofecoxib has been researched along with Sensitivity and Specificity in 18 studies
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sofosbuvir (SOF) and daclatasvir (DCS) are novel, recently developed direct acting antiviral agents characterized by potent anti-hepatitis C virus action." | 7.88 | Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits. ( Abo-Zeid, MN; Atia, NN; El-Gizawy, SM; El-Shaboury, SR, 2018) |
| "Sofosbuvir (SOF) and daclatasvir (DCS) are novel, recently developed direct acting antiviral agents characterized by potent anti-hepatitis C virus action." | 3.88 | Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits. ( Abo-Zeid, MN; Atia, NN; El-Gizawy, SM; El-Shaboury, SR, 2018) |
| "To examine the ability of rofecoxib prophylaxis to blunt the effect of monosodium urate (MSU) crystal inflammation induced in the rat subcutaneous air pouch." | 3.73 | Prophylactic effect of highly selective COX-2 inhibition in acute monosodium urate crystal induced inflammation in the rat subcutaneous air pouch. ( Chen, LX; Clayburne, G; Nalbant, S; Schumacher, HR; Sieck, MS, 2005) |
| "Forty two had progressed to Alzheimer type dementia during a five year follow up period and were considered to have predementia Alzheimer's disease at baseline." | 2.71 | Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? ( Scheltens, P; Verhey, FR; Visser, PJ, 2005) |
| " The method is suitable not only for the estimation of active ingredients in pharmaceutical dosage forms but also in vitro estimations in human plasma." | 1.33 | Development and validation of a reversed-phase liquid chromatographic method for separation and simultaneous determination of COX-2 inhibitors in pharmaceuticals and its application to biological fluids. ( Meena, S; Nagaraju, D; Rao, AR; Rao, RN, 2005) |
| " After validation, the method was used to study the pharmacokinetic profile of rofecoxib in 12 healthy volunteers after administration of a single oral dose (12." | 1.31 | Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans. ( Brune, K; Gillich, M; Mundkowski, R; Werner, D; Werner, U, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 16 (88.89) | 29.6817 |
| 2010's | 1 (5.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atia, NN | 1 |
| El-Shaboury, SR | 1 |
| El-Gizawy, SM | 1 |
| Abo-Zeid, MN | 1 |
| Carrasquer, G | 1 |
| Li, M | 1 |
| Spiegel, BM | 1 |
| Targownik, L | 1 |
| Dulai, GS | 1 |
| Gralnek, IM | 1 |
| Anderson, JJ | 1 |
| Bolognese, JA | 1 |
| Felson, DT | 1 |
| Rao, RN | 1 |
| Meena, S | 1 |
| Nagaraju, D | 1 |
| Rao, AR | 1 |
| Dahl, JB | 1 |
| Kehlet, H | 1 |
| Perse, M | 1 |
| Zebic, A | 1 |
| Cerar, A | 1 |
| Amini, M | 1 |
| Hamedani, MP | 1 |
| Vosooghi, M | 1 |
| Nabavi, M | 1 |
| Shafiee, A | 1 |
| Vintiloiu, A | 1 |
| Mullett, WM | 1 |
| Papp, R | 1 |
| Lubda, D | 1 |
| Kwong, E | 1 |
| Nalbant, S | 1 |
| Chen, LX | 1 |
| Sieck, MS | 1 |
| Clayburne, G | 1 |
| Schumacher, HR | 1 |
| Day, D | 1 |
| Furlan, A | 1 |
| Irvin, E | 1 |
| Bombardier, C | 1 |
| Visser, PJ | 1 |
| Scheltens, P | 1 |
| Verhey, FR | 1 |
| Hamama, AK | 1 |
| Ray, J | 1 |
| Day, RO | 1 |
| Brien, JA | 1 |
| Hsieh, YH | 1 |
| Lin, SJ | 1 |
| Chen, SH | 1 |
| Woolf, E | 1 |
| Fu, I | 1 |
| Matuszewski, B | 1 |
| Chavez-Eng, CM | 1 |
| Constanzer, ML | 1 |
| Matuszewski, BK | 1 |
| Werner, U | 1 |
| Werner, D | 1 |
| Mundkowski, R | 1 |
| Gillich, M | 1 |
| Brune, K | 1 |
1 review available for rofecoxib and Sensitivity and Specificity
| Article | Year |
|---|---|
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; | 2003 |
1 trial available for rofecoxib and Sensitivity and Specificity
| Article | Year |
|---|---|
Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase | 2005 |
16 other studies available for rofecoxib and Sensitivity and Specificity
| Article | Year |
|---|---|
Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits.
Topics: Animals; Antiviral Agents; Biological Availability; Carbamates; Chromatography, High Pressure Liquid | 2018 |
Effect of ibuprofen and rofecoxib transport parameters in the frog corneal epithelium.
Topics: Animals; Dose-Response Relationship, Drug; Epithelium, Corneal; Ibuprofen; In Vitro Techniques; Lact | 2002 |
Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost-Ben | 2003 |
Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Auranofin; Clinical Trials as Topic; Computer Simulatio | 2003 |
Development and validation of a reversed-phase liquid chromatographic method for separation and simultaneous determination of COX-2 inhibitors in pharmaceuticals and its application to biological fluids.
Topics: Butanones; Celecoxib; Chromatography, Liquid; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Lacto | 2005 |
Comment on: Gilron I, Orr E, Tu D, O'Neill JP, Zamora JE, Bell AC. A placebo-controlled randomized clinical trial of perioperative administration of gabapentin, rofecoxib and their combination for spontaneous and movement-evoked pain after abdominal hyste
Topics: Adult; Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Cyclooxygenase Inhibitors; Data In | 2005 |
Rofecoxib does not inhibit aberrant crypt foci formation but inhibits later steps in the development of experimental colorectal cancer: rofecoxib in experimental colon cancer.
Topics: Administration, Oral; Animals; Biopsy, Needle; Colorectal Neoplasms; Disease Models, Animal; Drug Ad | 2005 |
Pre-column derivatization of rofecoxib for determination in serum by HPLC.
Topics: Calibration; Chromatography, High Pressure Liquid; Cyclization; Cyclooxygenase 2 Inhibitors; Humans; | 2005 |
Combining restricted access material (RAM) and turbulent flow for the rapid on-line extraction of the cyclooxygenase-2 inhibitor rofecoxib in plasma samples.
Topics: Chromatography, High Pressure Liquid; Flow Injection Analysis; Gas Chromatography-Mass Spectrometry; | 2005 |
Prophylactic effect of highly selective COX-2 inhibition in acute monosodium urate crystal induced inflammation in the rat subcutaneous air pouch.
Topics: Animals; Arthritis, Gouty; Cyclooxygenase Inhibitors; Disease Models, Animal; Female; Inflammation; | 2005 |
Simplified search strategies were effective in identifying clinical trials of pharmaceuticals and physical modalities.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Back Pain; Clinical Trials as Topic; | 2005 |
Simultaneous determination of rofecoxib and celecoxib in human plasma by high-performance liquid chromatography.
Topics: Celecoxib; Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Humans; Lactones; Pyrazo | 2005 |
Simultaneous determination of celecoxib, meloxicam, and rofecoxib using capillary electrophoresis with surfactant and application in drug formulations.
Topics: Celecoxib; Chemistry, Pharmaceutical; Cyclooxygenase 2 Inhibitors; Electrophoresis, Capillary; Human | 2006 |
Determination of rofecoxib, a cyclooxygenase-2 specific inhibitor, in human plasma using high-performance liquid chromatography with post-column photochemical derivatization and fluorescence detection.
Topics: Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Humans; Lactones; Photochemistry; R | 1999 |
Determination of rofecoxib (MK-0966), a cyclooxygenase-2 inhibitor, in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection.
Topics: Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Humans; Lactones; Mass Spectrometry | 2000 |
Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans.
Topics: Adult; Area Under Curve; Atmospheric Pressure; Chromatography, High Pressure Liquid; Cyclooxygenase | 2001 |